Investigational drug · Phase 3
Andecaliximab
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Fibrodysplasia Ossificans Progressiva, Heterotopic Ossification (HO).
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
14
Any phase or sponsor naming "Andecaliximab"
First trial start
2024
Oct 25, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Andecaliximab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Fibrodysplasia Ossificans Progressiva
- Heterotopic Ossification (HO)
Largest trials
Live from ClinicalTrials.gov: studies naming "Andecaliximab" as an intervention, largest first.
- Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction AdenocarcinomaPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT02545504 · 432 participants · Start Oct 13, 2015 · Primary completion May 15, 2019
Drug: Andecaliximab; Placebo and 3 more · For: Gastric Adenocarcinoma
Sites: La Jolla, California; Los Angeles, California; Whittier, California · 134 sites in all
Gilead SciencesGilead Sciences (GILD)
NCT01803282 · 236 participants · Start Mar 29, 2013 · Primary completion Apr 23, 2019
Drug: Andecaliximab; Gemcitabine and 9 more · For: Pancreatic Cancer; Non-small Cell Lung Cancer; Esophagogastric Cancer and 2 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Bakersfield, California · 18 sites in all
- Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's DiseasePivotal-lookingTerminated
Gilead SciencesGilead Sciences (GILD)
NCT02405442 · 187 participants · Start Apr 30, 2015 · Primary completion Nov 30, 2016
Drug: Andecaliximab; Placebo · For: Crohn's Disease
Sites: Dothan, Alabama; Scottsdale, Arizona; Los Angeles, California · 74 sites in all
- Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative ColitisPivotal-lookingTerminated
Gilead SciencesGilead Sciences (GILD)
NCT02520284 · 165 participants · Start Sep 2015 · Primary completion Sep 2016
Drug: Andecaliximab; Placebo · For: Ulcerative Colitis
Sites: Dothan, Alabama; Wheat Ridge, Colorado; Lauderdale Lakes, Florida · 87 sites in all
- Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction AdenocarcinomaPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT02864381 · 144 participants · Start Sep 1, 2016 · Primary completion Nov 8, 2017
Drug: Andecaliximab; Nivolumab · For: Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma
Sites: Los Angeles, California; San Francisco, California; Chicago, Illinois · 34 sites in all
- A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)Pivotal-lookingActive, not recruiting
Ashibio IncIndustry
NCT06508021 · 92 participants (planned) · Start Oct 25, 2024 · Primary completion Feb 4, 2029
Drug: Andecaliximab; Placebo and 1 more · For: Fibrodysplasia Ossificans Progressiva
Sites: San Francisco, California; Rochester, Minnesota; Philadelphia, Pennsylvania
Gilead SciencesGilead Sciences (GILD)
NCT01831427 · 74 participants · Start Mar 28, 2013 · Primary completion Jan 5, 2015
Drug: Andecaliximab; Placebo to match Andecaliximab · For: Ulcerative Colitis
Sites: Monroe, Louisiana; Bethesda, Maryland; Chesterfield Township, MI 48047, Michigan · 16 sites in all
Gilead SciencesGilead Sciences (GILD)
NCT02862535 · 36 participants · Start Sep 20, 2016 · Primary completion Oct 25, 2019
Drug: Andecaliximab; S-1 and 3 more · For: Gastric Adenocarcinoma
Sites: Nagoya, Japan; Osaka, Japan; Tokyo, Japan
- Absolute Bioavailability, Safety, and Tolerability of Subcutaneous GS-5745 in Healthy AdultsCompleted
Gilead SciencesGilead Sciences (GILD)
NCT02209987 · 28 participants · Start Aug 2014 · Primary completion Oct 2014
Drug: GS-5745 SC; GS-5745 IV · For: Ulcerative Colitis
Sites: Christchurch, New Zealand
- Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid ArthritisCompleted
Gilead SciencesGilead Sciences (GILD)
NCT02176876 · 18 participants · Start Aug 2014 · Primary completion Apr 2015
Drug: GS-5745; Placebo to match GS-5745 · For: Rheumatoid Arthritis
Sites: Prague, Czechia; Balatonfüred, Hungary; Budapest, Hungary · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Matrix metalloproteinases in intestinal fibrosis and fibrostenosing Crohn's disease: Current evidence, mechanistic hypotheses, and translational challenges.
Kochkarian T, Lopez KM, Ou R, et al. · Inflamm Bowel Dis 2026
- Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.
Gordon M, Sinopoulou V, Akobeng AK, et al. · Cochrane Database Syst Rev 2026
- Biological Therapy and Small Molecules for Adults With Crohn's Disease: Systematic Review and Network Meta-Analysis.
Gorski D, Lazo REL, de Souza DA, et al. · Pharmacotherapy 2025
- Metabolism and response to stress gene signatures reveal ulcerative colitis heterogeneity and identify patients with increased response to therapy.
Linggi B, Filice M, Sangiorgi B, et al. · J Crohns Colitis 2025
- Inside a Metastatic Fracture: Molecular Bases and New Potential Therapeutic Targets.
Bruschi A, Sambri A, Fiore M, et al. · Cancer Med 2025
- Text Mining and Drug Discovery Analysis: A Comprehensive Approach to Investigate Diabetes-Induced Osteoporosis.
Wang C, Hu Y, Liang F · Int J Med Sci 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.